Fig. 4

Type-specific expression of human genes that corresponds with type-specific EBNA2 and hTF partner genomic occupancy. One example is shown for each of the following: shared EBNA2 binding (A: MYC, chr8:128,168,540–128,775,448), type 1 specific EBNA2 binding (B: CXCR7, chr2:237,441,986–237,513,677), and type 2 specific EBNA2 binding (C: CD21, chr1:207,601,245–207,633,439). For each locus, the normalized counts (DESeq2) of the human gene are shown above a UCSC Genome Browser screenshot depicting (top to bottom): the gene, chromatin accessibility, EBNA2 binding (ChIP-seq), and hTF binding (ChIP-seq) in each cell line. Type-specific and shared EBNA2 peaks are indicated above the EBNA2 ChIP-seq tracks. In panel A, previously identified type 1 EBNA2 super enhancers at the MYC locus ([57]; MYC ESE2, chr8:128,312,176–128,320,865; MYC ESE1: chr8:128,215,588–128,228,144) are boxed and labeled. Data from biological replicates are shown throughout. A = AG876; J = Jiyoye; M = Mutu-III; G = GM12878; L = LCL. Data ranges: MYC Overview [ATAC-seq (0 to 5; Mutu-III 0 to 0.7); EBNA2 ChIP-seq (0 to 14); EBF1 ChIP-seq (0 to 5); SPI1 ChIP-seq (0 to 5); RBPJ ChIP-seq (0 to 5)]; MYC 525 ESE [ATAC-seq (0 to 3; Mutu-III 0 to 0.4); EBNA2 ChIP-seq (0 to 13); EBF1 ChIP-seq (0 to 5); SPI1 ChIP-seq (0 to 1); RBPJ ChIP-seq (0 to 2)]; MYC 428 ESE [ATAC-seq (0 to 4; Mutu-III 0 to 0.7); EBNA2 ChIP-seq (0 to 8); EBF1 ChIP-seq (0 to 4); SPI1 ChIP-seq (0 to 5); RBPJ ChIP-seq (0 to 5)]; CXCR7 [ATAC-seq (0 to 3; Mutu-III 0 to 0.4); EBNA2 ChIP-seq (0 to 10); EBF1 ChIP-seq (0 to 4)]; CD21 [ATAC-seq (0 to 8; Mutu-III 0 to 0.4); EBNA2 ChIP-seq (0 to 6); SPI1 ChIP-seq (0 to 3); RBPJ ChIP-seq (0 to 3)]